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Bacterial resistance to antibiotics poses a serious health threat. Since 
research into new antibiotics is not pro-
gressing at the same rate as the develop-
ment of bacterial resistance, widespread 
calls for alternatives to antibiotics have 
been made. Phage therapy is an ideal 
alternative candidate to be investigated. 
However the success of phage therapy 
may be hampered by a lack of invest-
ment support from large pharmaceutical 
companies, due to their narrow spec-
trum of activity in antibiotics, very large 
costs associated with clinical trials of 
the variety of phages needed, and regu-
latory requirements remaining unclear. 
Intellectual property is difficult to secure 
for therapeutic phage products for a vari-
ety of reasons, and patenting procedures 
vary widely between the US and the EU. 
Consequently, companies are more likely 
to invest in phage products for decon-
tamination or veterinary use, rather 
than clinical use in humans. Some still 
raise questions as to the safety of phage 
therapy overall, suggesting the possibil-
ity of cytotoxicity and immunogenicity, 
depending on the phage preparation and 
route. On the other hand, with patients 
dying because of infections untreatable 
with conventional antibiotics, the ques-
tion arises as to whether it is ethical not to 
pursue phage therapy more diligently. A 
paradigm shift about how phage therapy 
is perceived is required, as well as more 
rigorous proof of efficacy in the form of 
clinical trials of existing medicinal phage 
products. Phage therapy potential may 
be fulfilled in the meantime by allow-
ing individual preparations to be used 
on a named-patient basis, with exten-
sive monitoring and multidisciplinary 
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team input. The National Health Service 
and academia have a role in carrying out 
clinical phage research, which would be 
beneficial to public health, but not neces-
sarily financially rewarding.
Antimicrobial resistance is a major 
international public health threat, which 
can severely limit treatment choice in 
clinical settings, making infections more 
difficult or even impossible to treat. The 
severity of the threat is such that there 
are even suggestions of a return to pre-
penicillin days, in the absence of adequate 
countermeasures.1 The development of 
new classes of antibiotics is not keeping 
pace with the speed at which bacteria are 
developing resistance. Reports of antibi-
otic-resistant bacteria isolated in hospitals 
already exist.2
In the late 1960s and early 1970s, the 
success of antimicrobial medicines cre-
ated an illusion that infectious diseases 
had been defeated.3 Since that time, bac-
terial infections have made a worrying 
comeback, and as a consequence, strategic 
documents were issued by the WHO.4 
In April 1998, the House of Lords Select 
Committee on Science and Technology 
published the report, Resistance to 
Antibiotics and other Antimicrobial Agents, 
which recognized the severity of the situ-
ation.5 In response, the Department of 
Health published a decisive strategic plan, 
which defined eight action areas, one of 
which was ‘to encourage the development 
of new and novel agents/technologies to 
detect, prevent and treat infection to over-
come resistance.’
As long ago as 2000, this UK 
Antimicrobial Resistance Strategy and 
Action Plan stated very clearly that 
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alternatives to antibiotic treatment must 
be sought in the fight against antimicro-
bial resistance.6 The UK Government 
has recognized the predicament and has 
clearly encouraged the development of 
alternative agents, which encompasses 
phage therapy.
The Ethics of Phage Therapy
To date, no debate about the ethics of 
phage therapy based on bioethical theories 
has been published. Attention has been 
focused on presenting positive evidence 
of human and animal case studies and on 
possible reasons why phage therapy has at 
times failed and may do so in the future. 
With court cases and public pressure forc-
ing licensing authorities and governments 
to enable fast-track licensing schemes for 
drugs treating HIV, MS and cancer, it is 
interesting why no similar scenario has 
been seen regarding phage therapy. A 
major reason is the absence of convincing 
evidence of phage safety and efficacy in 
humans in the form of modern double-
blind clinical trials.
In the UK, there is no national data 
published reflecting the mortality rate 
due to bacterial infections other than 
Staphylococcus aureus (including MRSA) 
and Clostridium difficile.7,8 There is also a 
lack of available national statistics repre-
senting the morbidity and mortality asso-
ciated with bacterial strains untreatable 
with antibiotics. Such data, if collected, 
should highlight the reality of casualties 
due to an absence of alternatives to the cur-
rently available antibiotics. Governments 
may be understandably reluctant to collate 
and publish such figures; however, pres-
sure groups of patients may force decision 
makers to invest in alternatives to cur-
rently available therapy options.
The Declaration of Helsinki states: “In 
the treatment of a patient, where proven 
prophylactic, diagnostic and therapeutic 
methods do not exist or have been inef-
fective, the physician, with informed con-
sent from the patient, must be free to use 
unproven or new prophylactic, diagnostic 
and therapeutic measures, if in the phy-
sician’s judgment it offers hope of saving 
life, re-establishing health or alleviating 
suffering. Where possible, these measures 
should be made the object of research, 
designed to evaluate their safety and effi-
cacy. In all cases, new information should 
be recorded and, where appropriate, 
published.”9
Considering reports that phage therapy 
has been widely successful even when used 
as a last resort in infections non-respon-
sive to antibiotics,10-12 a question arises: Is 
it even ethical to continue not pursuing 
phage therapy in the UK? Phage therapy 
was suggested as a treatment option in the 
context of the recent E. coli O104 outbreak, 
which resulted in many fatalities.13,14 No 
clinical trials on any therapeutic options 
for patients affected by the Shiga toxin-
induced hemolytic uremic syndrome were 
available at the time of the outbreak, and 
some of the chosen therapy may have 
been harmful,15 yet phage therapy was 
not even considered.13 Notably, given the 
circumstances of the outbreak, the use of 
an unapproved medicinal product such as 
phage would have been allowed under EU 
legislation.16
Even if this approach is deemed too 
risky, the exceptionally good track record 
and safety profile of topically used phage 
virtually begs for further exploration of 
therapeutic use.
Following the bioethical concept of 
non-maleficence, after Beauchamp and 
Childress17,18 who direct physicians to 
refrain from harming a patient regard-
less of intent, it could be debated whether, 
and under which circumstances, patients 
should have phage therapy made avail-
able to them. The concept of beneficence 
encompasses weighing the risks of using a 
given treatment vs. the benefits, and phage 
therapy should also be considered under 
this directive. The next logical step is to 
explore what the limitations are to bringing 
therapeutic phage products to the patient.
Safety of Phage:  
Safety of Phage Preparations
There is an implied understanding 
that phages are inherently safe, using the 
argument that phages are abundant in the 
environment and we are already exposed 
to them constantly, both topically and 
enterically.19 An additional argument is 
that they have been used so extensively for 
therapeutic purposes in some parts of the 
world with virtually no reports of harm, 
indicating that negative effects must be 
subtle or at least relatively minor.19-21 
Additionally, Barrow and Soothill (cit-
ing Ochs, 1971) pointed out that phages 
have been used to test antibody function 
in immunodeficient patients, implying 
that phages are non-toxic and seeing no 
evidence to the contrary.22 Even taking 
these arguments into account, it is sur-
prising that no phage cytoxicity studies 
have been published, and any assump-
tions as to whether phage may be safe or 
not should be challenged and verified by 
scientific experiments. According to Pirisi 
(2000), Du Bow summed this up con-
cisely: “What we think we know about 
phages has to be verified and then deemed 
reproducible, safe and effective” under 
therapeutic conditions.23
There are further examples of phage 
being “generally considered as safe”:
• When some vaccines were found to 
have been contaminated with phage in the 
1970s on a very large scale, an Executive 
Order was issued to permit the continued 
use of the contaminated vaccines. No ill 
effects were reported.24,25
• In 2006, the US FDA designated a 
mixture of Listeria monocytogenes phages 
for use in ready to eat foods as GRAS 
(Generally Recognized as Safe). This pro-
vides another argument to support the 
safety of phage.26
However, phage therapy may entail sin-
gle or repeated use of concentrated phage 
preparations with high titers in a patient, 
administered by a variety of routes, which 
is quite different to ingesting the quanti-
ties contained in food products. There 
is also a clear distinction to be made 
between IV use, which has seldom been 
implemented, and topical applications of 
phage at relatively low concentrations, for 
which there is a great deal of experience.
Not all phages are safe to humans under 
all circumstances. For example, phage-
associated conversion of Tox− Streptococcus 
pyogenes into Tox+ bacteria in vivo has been 
described in the literature, with the concern 
that genes for other phage-associated toxins 
like botulinum, shiga and diphtheria toxins 
may be transferrable by particular related 
phages.27 It needs to be emphasized, how-
ever, that it is generally temperate phages 
that can induce these toxins, and a very 
different type of phages—professionally 
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lytic phages—are used for phage therapy. 
Additionally, in modern phage therapy, 
complete genome sequencing of each phage 
can help with avoiding use of phages which 
carry toxin or virulence genes, or have 
mechanisms to acquire these attributes by 
recombination with resident prophages and 
carry them on to other hosts.
It is also important to differentiate 
between the safety of a specific phage and 
the safety of a particular phage prepara-
tion. In the early days of phage therapy, 
several authors reported cases of insuffi-
ciently purified phage preparations or the 
presence of chemical contaminants and 
attributed treatment failures to this prob-
lem.19,23,28 Thus, the safety and sterility of 
the phage preparations must be ensured 
sound design and Good Manufacturing 
Practice. Past treatment failures are a 
reminder that any claims of safety need to 
be corroborated by scientific evidence.
Cytotoxicity and Safety of Phage
It is surprising that there appear to be no 
comprehensively conducted in vitro cyto-
toxicity experiments for phage, designed 
similarly to routine cytotoxicity testing of 
chemical compounds. The reasons may be 
that phages are assumed to be ‘clinically 
safe’, due to a lack of reports of adverse 
effects during human and animal experi-
mentation and possibly decades of reported 
human phage therapy mainly in Georgia, 
Russia and Poland. A lack of in vitro cyto-
toxicity studies also extends to lack of data 
on phage cytotoxicity in wound models. It 
needs to be borne in mind that therapeutic 
phage would be locally applied in concen-
trations of approximately 108 phages per 
milliliter, at volumes of several milliliters, 
to cells which are involved in a very com-
plex immune system involving cytokines 
and other biochemical messenger systems; 
any minor interference by phage prepara-
tions in the wound healing and graft-take 
processes could potentially affect clinical 
outcomes significantly.
There is a further potential issue that is 
not generally considered. Phages are struc-
tures within the 1–100 nm size range and 
could be seen as nanoparticles. It may be 
useful to study phages in a similar way 
to nanoparticles, investigating surface 
charge, aggregation29 and nanotoxicity. 
The migration and incorporation of simi-
larly sized nanoparticles into mammalian 
cells has been investigated30 and may offer 
an increased insight into how phage could 
operate in a complex system and further 
evidence of their safety at therapeutic doses.
Immunogenicity
Phage, when administered intra-
venously, may evoke an immune 
response,28,31 which may be stimulated by 
some component in the phage preparation 
and/or by the phages themselves. Bacterial 
products remaining in the preparation 
were sometimes suggested to have pos-
sibly contributed to phage therapy fail-
ure in the past.31 At the same time, there 
are indications that using sterile-filtered 
crude phage lysates may actually improve 
treatment outcomes by stimulating the 
immune response.32 In fact, immune sys-
tem stimulation is the directed purpose of 
the Staph Phage Lysate marketed in the 
US by Delmont Labs since the 1940s for 
veterinary staphylococcal skin infections.
Repeated exposure to the same phage 
strain may also activate the adaptive 
immune system and result in antibody 
production,33 decreasing the efficacy of a 
particular phage for its intended patho-
genic target. It is unknown whether puri-
fied phage can elicit allergic reactions, 
though immune responses can elimi-
nate phage under certain conditions.22 
While crude lysates may actually improve 
treatment outcomes by stimulating the 
immune response, in contrast purified 
phage preparations may have some immu-
nosuppressive function; both types can 
modulate cytokines.32-35
Whether or not any kind of effect of 
phage on the immune system is desir-
able,32,36,37 it is debatable whether intra-
venous phage therapy will be accepted 
as a serious therapy option until clear 
evidence has been presented exploring 
the nature and extent to which systemic 
phage administration affects the human 
immune response.
Can Human Phage Therapy  
be Profitable?
For a pharmaceutical product to be 
profitable, the income generated from it 
must exceed the initial investment. For 
phage therapy both the profit and the 
investment factors remain unknown. To 
bring a new licensed drug to the mar-
ket can cost as much as $400–800 mil-
lion, which can constitute a hindrance to 
any new drug development.38 Since no 
licensed phage product for human therapy 
has yet reached the Western market, the 
costs remain unknown.
The pharmaceutical industry has not 
displayed much interest in phage therapy. 
The reasons for the low level of interest are 
closely related to the reasons for the lack 
of new antibiotics. The return on invest-
ment from new antimicrobial agents is less 
than that from other drug classes. They 
are only required for short courses, rather 
than as a continuous therapy as required 
for chronic conditions.39 Due to aging 
populations, drug discovery efforts are 
largely focused on medicines that treat 
chronic medical conditions, which com-
monly occur in the elderly.
The tendency in recent years has been 
for pharmaceutical companies to focus 
most of their research on improving 
well-established structures,31 rather than 
attempting to discover structurally novel 
compounds, and this is particularly true 
in terms of antibacterial agents.1 There 
is a tension here between the interests of 
public health and of the pharmaceutical 
industry. Limiting the use of the new, 
high-priced broad-spectrum antibiot-
ics is in the interest of public health, to 
discourage resistant bacterial strains from 
developing. To this end, it is important to 
continually introduce new drug formu-
laries but to enforce prescribing protocols. 
The appropriate measures of antimi-
crobial stewardship to extend the useful 
life of antibiotics have a downside: they 
discourage the more widespread use of 
newly developed, more expensive antimi-
crobials, which in turn negatively impacts 
sales.39 It may be more in the interest of 
patients to develop selective antibacterial 
agents, specific for a small group of patho-
gens, rather than more broad-spectrum 
antibiotics; however this would also limit 
the indications and the market of such 
product. For these reasons some large 
pharmaceutical companies have indicated 
that they are limiting or entirely aban-
doning anti-infective research, except 
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for anti-HIV agents,40 which are more 
profitable.
A range of companies specializing in 
bacteriophage have appeared or become 
established in recent years, demonstrating 
that there is growing commercial interest 
in phage therapy. However, the compa-
nies currently undertaking research and 
development regarding the use of phages 
are all small to medium-sized enterprises, 
rather than the large multinational com-
panies traditionally associated with drug 
development. A prominent example of 
this is Ampliphi Biosciences/Biocontrol 
Ltd. UK, which is facing high regulatory 
hurdles, the need for substantial finan-
cial investment and the prospect of hav-
ing to finance controlled clinical trials.13 
With such high investment cost at stake, 
phage therapy investors will want to pro-
tect their intellectual property (IP) on any 
phage product. The issues around IP are 
discussed in more detail elsewhere.13,14 In 
short, private companies will be reluctant 
to invest in a product that may be diffi-
cult, or impossible, to patent. To add to 
this challenge, the US and EU patenting 
pathways differ.14
Patenting of phages that have been 
isolated from the environment (not modi-
fied) is currently possible, but it provides 
limited IP protection.14 Investing in a 
product without full IP and particularly 
patent protection is unlikely to be finan-
cially viable. In addition competitors may 
easily isolate similar phages from the envi-
ronment. For these reasons some com-
panies are exploring other avenues, such 
as patenting specific phage sequences, 
pursuing novel concepts like using phage 
deficient in their lytic system,41 using 
genetically engineered phage as a vector 
for lethal genes,42 or molecules,43 employ-
ing phage products such as cell hydro-
lases, also known as lysins,44 or modified 
phage products.45 Formulation of delivery 
systems may offer another avenue for IP 
protection, for example dressings, skin 
graft material or sutures impregnated with 
phage.
The need for high financial investment, 
coupled with the absence of a guarantee of 
a market, means that phage therapy may 
be considered inherently financially unat-
tractive. If phage product development if 
solely left up to the private sector, future 
research efforts may be focused on finding 
phage products aimed at providing finan-
cial returns, rather than combating infec-
tious disease
Profitable phage products may not 
necessarily be those intended for human 
therapeutic use, but for decontamination 
or for veterinary use, as the cost of bring-
ing a product to the market would be low 
compared with the extensive clinical trials 
required for licensed human medicines. 
Public-private partnerships and involve-
ment of the National Health Service 
(NHS) may be required to let phage live 
up their full potential in combating the 
crisis of antibiotic resistance.
Regulatory Agency Approval
Phage-based products intended for 
clinical use are still not explicitly covered 
by existing regulatory guidelines;46 how-
ever ListshieldTM, a product for spray-
ing onto ready-to eat meat and poultry 
products, was successfully given full 
Food Additive approval by the US FDA 
in 2006,47 while a European anti-Listeria 
phage product was given GRAS (generally 
regarded as safe, so no objection) status by 
the US FDA, also in 2006.48
There has been much debate how regu-
latory agencies would and ought to regu-
late therapeutic phage.49,50 Should phage 
be considered a ‘biological medicinal prod-
uct’ (Commission Directive 2001/83/
EC)16 or, as suggested by Verbeken et al.,51 
an ‘advanced therapy medicinal product’ 
(Commission Directive 2003/63/EC)?52 
For the former, clinical trials will need to 
be conducted for each phage strain, while 
the latter is based on manufacturing pro-
cesses focused on various gene transfer 
produced bio-molecules, with legislation 
making allowances that “it may not be 
possible to perform conventional clinical 
trials” (Commission Directive 2003/63/
EC).52
The question of how to legally clas-
sify phage products is important. This 
is not purely an academic debate within 
the phage community, as the outcome of 
this argument may make the difference 
between phage therapy becoming a suc-
cessful mainstream treatment option or 
not. The crux of the debate lies in whether 
the emphasis should be placed on process 
controls or on characterizing each single 
phage strain used for therapeutic pur-
poses. If process controls are the determin-
ing factor, updating phage cocktails with 
more effective phage would become much 
easier and cheaper. Otherwise a clinical 
trial with all its cost implications might 
need to be conducted after each phage 
cocktail modification.
Kutter and Sulakvelidze19 pointed 
out that updating with new strains is 
not unprecedented in the West and sug-
gested therapeutic phage could be treated 
similarly to influenza-vaccines in terms of 
regulation. The authors report that in the 
former Soviet Union only the ‘principal’ 
phage preparation and manufacturing 
and quality control protocols needed offi-
cial approval; a similarly flexible approach 
in the West would foster the success of 
phage therapy. The advantage of allowing 
licensing of therapeutic phage products 
as a biotechnology product would be that 
it would allow for continuous changes of 
phage strains in response to evolution of 
dominant antibiotic-resistant bacterial 
strains and allow phage preparations to 
have maximum clinical effectiveness.
With Listshield™ the FDA allowed 
updating of the host strains as well as 
substitution of similar well-character-
ized phages. There is hope that a similar 
approach will be taken by regulators when 
it comes to licensing human phage ther-
apy products.53
Absence of Rigorous Proof  
of Efficacy: Funding for Clinical 
Phage Research
Despite an overwhelming number of 
reports that phage has been used success-
fully for a multitude of infections, there 
remains an urgent need for double blind, 
placebo-controlled studies.46 Factors dis-
cussed previously, particularly hurdles 
involving licensing issues and lack of pat-
entability of most phages, are most likely 
to discourage investors. Clinical trials are 
cost intensive, requiring years of resources 
and qualified support, but without them 
phage therapy has little chance of success.
As the interest of the pharmaceutical 
companies is necessarily in maximizing 
their short and medium term profits, it 
may be the case that they will under-invest 
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in novel techniques/treatments that bring 
better clinical results when these new treat-
ments are not profitable on a sufficiently 
short timescale (i.e., not fast enough). It is 
surely the role of a nationalized health ser-
vice with a remit to prioritize patient out-
comes, to identify and step into such gaps, 
either by providing ring fenced funding 
or at least by co-ordinating research, oth-
erwise opportunities for the development 
of beneficial new technologies may be 
missed.
As the NHS is publicly funded, one way 
for phage therapy to gain a foothold in the 
UK would be to secure NHS funding and 
work within the structure of the NHS, 
possibly using unlicensed phage prepa-
rations on a named-patient basis under 
the emergency clause. In the future the 
potentially strongest driving force behind 
phage therapy may become the public, 
provided phage therapy is appropriately 
lobbied. This may be difficult as individ-
ual researchers may not have the resources 
to start PR campaigns and patient groups 
may be unaware of the potential of phage 
therapy. However mainstream media, 
popular science publications, science blogs 
and other internet-based media may help 
in communicating the urgency of finding 
alternatives to antibiotics and facts about 
phage therapy.
Paradigm Shifts
Phages are biologically active particles, 
genetically changeable, with very narrow 
activity spectra and display entirely dif-
ferent pharmacokinetics to antibiotics. As 
with any paradigm shift, the ‘old’ anti-
biotic paradigm—the concept of using 
chemicals to treat bacterial infections, is 
needed to explore the new paradigm—
that of phage therapy. Yet, although the 
outcome—the killing of bacteria—is sim-
ilar, the means by which this is achieved 
is entirely different. The kinetics of phage 
therapy are very different from antibiotic 
pharmacokinetics54 and these differences 
have a dramatic impact on the use of 
phage, compared with antimicrobials.55
There is a serious risk that if these dif-
ferences are not reiterated to healthcare 
professionals, to peers and particularly 
to licensing authorities and accounted 
for when attempting phage therapy, the 
nature and potential of phage may be mis-
understood and phage therapy may fail a 
second time in the West. In practice this 
may be overcome by treating therapeutic 
phage preparations in the same way as a 
restricted antibiotic, by dispensing to indi-
vidual patients only on specialist consul-
tant microbiologist advice, after rigorous 
testing of suitability.
Conclusion
Phage therapy has undoubtedly huge 
potential, but whether it will be fulfilled 
will depend on a variety of factors. The 
multi-national pharmaceutical companies 
maybe reluctant to invest in phages that 
maybe difficult to patent or, if patented, 
may provide limited IP protection. It is 
most likely that the pioneers in phage ther-
apy will remain in the ranks of academia 
and small spin-off companies, which may 
mean lengthy delays before phage therapy 
reaches mainstream therapeutics.
Therapy with phages that are hard 
to isolate or those with a narrow spec-
trum may be seriously hampered by the 
absence of available strongly lytic phages. 
This may be remedied by international 
collaborations, the building of national 
phage libraries and using phage cock-
tails. Licensing authorities would need to 
be convinced of the benefits of regularly 
updating phage mixtures; alternatively, 
phage may be used in unlicensed form 
on a named-patient basis in collaboration 
with physicians.
Successful phage therapy is likely to 
require a certain minimum infrastructure, 
which private companies or academia 
alone may not easily provide. Bacteria 
would need to be isolated from the patient, 
rapidly identified, and screened against 
available approved phage cocktails or 
individual phage strains, to ensure maxi-
mum clinical efficacy. On the basis of 
these results, a specialized phage cocktail 
might then be mixed and formulated into 
a medicinal product in an aseptic suite, as 
is already done for intravenous antibiotics 
and chemotherapeutics in hospital phar-
macy departments. Within a large hospi-
tal environment, particularly with close 
ties to academia, an appropriate infra-
structure, which may require effective 
cooperation between scientists, clinicians 
and other healthcare professionals, already 
exists. From a public health perspective it 
could be justified that public money be 
spent on bringing phage therapy for key 
antibiotic-resistant bacteria into exten-
sive clinical trials. This may need to be 
done, at least in the UK, by collaborations 
between the NHS, academia and private 
phage companies.
Phage preparations may need to be 
treated like restricted antibiotics, dis-
pensed on a named patient basis with 
consultant microbiologist involvement. 
Adequate phage prescribing and admin-
istration may need to be monitored by 
microbiologists and pharmacists, and 
excellent communication with the rest of 
the healthcare team would be essential.
Failing to pursue the avenue of phage 
therapy may become ethically unaccept-
able, when weighing risks against benefits. 
However, it appears that pharmaceutical 
companies are unlikely to invest in phage 
therapy for various reasons. It will need to 
become unacceptable in the public eye for 
patients to routinely die of infectious dis-
eases that might have been curable with 
phage.
Looking for alternatives to antibiotics 
to treat bacterial infections would be in 
the spirit of the UK action plan. Whether 
phage therapy ultimately can play a sig-
nificant role in dealing with the looming 
antibiotic crisis remains to be seen, but at 
the very least investigating it as a potential 
treatment option in combating bacterial 
diseases would be in line with government 
recommendations and perhaps common 
sense.
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Note
Dr. Alexandra Henein died in February 
2013, just after submitting revisions of 
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this paper. Although she had been living 
with scleroderma since her diagnosis in 
2010, she continued to work until only a 
few days before her death. Her illness took 
her away from lab work, but she still took 
great pleasure in writing and in teaching. 
Her interest in therapeutic use of phage 
was long standing, being the subject of 
her PhD thesis in clinical pharmacy from 
Brighton University, and she remained 
convinced of its merits as she continued 
her work on antibiotic stewardship as 
a member of the Royal Pharmaceutical 
Society. She fought her illness with 
strength and bravery, and will be sorely 
missed by her many friends. She is sur-
vived by her husband Dr. Neil McNair, 
whom she married in July 2012.
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